Lentiviral Solutions: Fast Lane To The Clinic

Developing a lentiviral-based gene-modified cell therapy is a complex and resource-intensive journey that often faces high costs, long timelines, and strained teams. Programs that use multiple vendors or a "do-it-yourself" approach often encounter roadblocks, including navigating fragmented IP, using unqualified suppliers, and dealing with technical challenges during scale-up.

Delays of 12-18 months can occur in the Research & Discovery phase due to multiple rounds of vector redesign driven by low transduction efficiency, the risk of insertional mutagenesis, or envelope protein instability. Later, in the Preclinical and Early Phase Clinical stages, further vector rework or optimization engineering can add another 2-18 months of delay.

A smarter, more streamlined approach to the clinic exists. By partnering with a single, experienced provider, you can secure timelines, prevent delays, and gain full traceability and documentation. This approach offers phase-appropriate manufacturing, ready-to-order constructs, and smooth tech transfer to avoid late-stage surprises.

Want to learn how a single partner can support you throughout your entire journey? Explore the full infographic to see a detailed side-by-side comparison of the traditional path versus the streamlined approach.